No Data
Report for the third quarter of 2024 of Liaoning Chengda Biology Co., Ltd.
Liaoning Chengda Biotechnology Co.,Ltd.'s (SHSE:688739) Business Is Trailing The Market But Its Shares Aren't
2024 Semi-Annual Report of Liaoning Chengda Biology Co., Ltd.
Summary of the 2024 semi-annual report of Liaoning Chengda Biology Co., Ltd.
Chengda Biotech (688739.SH): The net income in the first half of the year was 0.22 billion yuan, a year-on-year decrease of 33.99%.
Gelonghui, August 29th, Chendasheng Bio(688739.SH) disclosed the semi-annual report for the year 2024. During the reporting period, the company achieved a revenue of 0.881 billion yuan, a year-on-year increase of 1.08%; net income attributable to the parent company was 0.22 billion yuan, a year-on-year decrease of 33.99%; non-GAAP net income was 0.211 billion yuan, a year-on-year decrease of 31.86%; basic earnings per share was 0.53 yuan.
Chengdu Sincerity Bio (688739.SH) released its semi-annual performance, with a net income of 0.22 billion yuan, a year-on-year decrease of 33.99%.
Chengdu Bio (688739.SH) disclosed its 2024 interim report, reporting that the company achieved a revenue of 8.81...
Liaoning Chengda Biotechnology Co.,Ltd.'s (SHSE:688739) On An Uptrend But Financial Prospects Look Pretty Weak: Is The Stock Overpriced?
No Data
